Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
The study is being conducted to evaluate the efficacy and safety of Camrelizumab (200mg,q2w) combined with Apatinib(250mg qd) in subjects with PD-L1 positive relapsed or advanced non-small cell lung cancer.
PD-L1 Positive Non-small Cell Lung Cancer
BIOLOGICAL: Camrelizumab 200mg|DRUG: Apatinib Mesylate 250mg|DRUG: Pemetrexed disodium for injection|DRUG: Paclitaxel injection|DRUG: Carboplatin
Progression Free Survival (PFS) assessed by Independent review committee (IRC), Progression Free Survival, defined as the time from randomization to the first occurrence of disease progression as determined by IRC with use of Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or death from any cause, whichever occurs first., up to 2 years|Overall survival, Overall survival is the time interval from the date of randomization to death due to any reason or lost of follow-up, up to 2 years
PFS assessed by investigator, Progression-Free-Survival, up to 2 years|Objective Response Rate, Objective Response Rate, determined using RECIST v1.1 criteria, defined as best overall response (complete or partial response) across all assessment time points, At the time point of every 6 weeks，up to 2 years|Disease Control Rate, Disease Control Rate, determined using RECIST v1.1 criteria, At the time point of every 6 weeks，up to 2 years|Duration of Response, Duration of Response, determined using RECIST v1.1 criteria, Up to 2 years|Time to Treatment Failure, Time to Treatment Failure, defined as the time from randomization to treatment discontinuation., Up to 2 years|Adverse Events and Serious Adverse Events, Adverse Events and Serious Adverse Events, from the first drug administration to within 90 days for the last Camrelizumab dose
The study is being conducted to evaluate the efficacy and safety of Camrelizumab (200mg,q2w) combined with Apatinib(250mg qd) in subjects with PD-L1 positive relapsed or advanced non-small cell lung cancer.